American biopharmaceutical company at Bridgewater in New Jersey, the successor to Transave of Monmouth Junction, which had developed liposomal medicines given by inhalation before merging into Insmed in 2010. That work became Arikayce, an inhaled liposomal amikacin approved for refractory lung infection caused by Mycobacterium avium complex, and the company now also develops brensocatib and treatments for pulmonary and rare diseases.
コメントはありません。
評価とコメントを残す